castle trial
Stop Using CASTLE - Chronic Disease Management Falls Short
CASTLE data shows a 52% remission rate after only two infusions, yet chronic disease management still falls short of expectations. The trial’s rapid impact contrasts sharply with the slow, incremental gains of conventional biologics, prompting a hard look at current care pathways. Medical Disclaimer: This article is for informational